LumiThera Acquires MacuLogix, an AMD Diagnosis Firm

LumiThera, a company offering photobiomodulation (PBM) treatment tech for ocular damage and disease, has purchased MacuLogix, a company that specializes in diagnosis of dry age-related macular degeneration (AMD) patients and developer of the wearable AdaptDX Pro dark adaptometer.
 
Launched in 2020 and available in the U.S., Canada, EU, and other countries, AdaptDX Pro helps measure dark adaptation, which is used to diagnose dry AMD in patients earlier than other technologies.
 
“The core technology measures the inability to visually adapt to low levels of light, a key clinical marker seen in patients with early AMD. Dark adaptation technology has been validated in 42 peer-reviewed papers,” Greg Jackson, Ph.D., former MacuLogix chief technology officer and co-founder told the press. “Over 1 million AdaptDX tests have been performed and about 200,000 patients have been newly diagnosed.”
 
The announcement comes on the heels of the company’s positive 13-month, 100-patient U.S. LIGHTSITE III treatment data in intermediate dry AMD patients with the Valeda light delivery system. The study showed improvements in best corrected visual acuity in intermediate dry AMD subjects with over 50% showing a line or better improvement on the eyechart with a mean of 9.7 letters gained for the responders.
 
“AdaptDx Pro can identify dry AMD patients at the earliest timepoint, in advance of pathology, and before vision loss,” stated Clark E. Tedford, Ph.D., president and CEO, LumiThera. “The AdaptDx wearable, light-based early diagnostic for dry AMD adds a complementary assessment of retinal health to the LumiThera product line, further expanding LumiThera’s synergistic platform of products for eye care professionals. We are excited to combine diagnosis, treatment, and monitoring platforms to provide a complete solution for dry AMD patients.”
 
The company also acquired the Diopsys visual evoked potential (VEP) and electroretinogram (ERG) vision testing technology in November.